Omeros shares oversold, secondary endpoint met, says Maxim Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
Omeros sees FY15 OpEx $110M-$120M For 2015, the company anticipates that operating expenses will be in the $110M-$120M range with non-cash expenses of approximately $15M. This guidance is largely based on the continued preparations for the full-scale U.S. launch of Omidria as well as the continued development of the company's product pipeline.